Clinical Trial

A Study of AZD0120 in Autoimmune Diseases

Study acronym: AURORA
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).
Protocol Amendment History 1 change
notable Trial sites expanded: 18 -> 22 locations 2026-07-29
Trial Details
NCT Number NCT07295847
Lead Sponsor AstraZeneca
Conditions Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Enrollment 27 participants
Start Date 2026-01-09
Primary Completion 2028-02-22 (estimated)
Study Completion 2028-02-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-28